BNF publication version 2.1.18 (android) updated may 2019

The description of BNF

BNF Publications have developed an app that gives up-to-date offline reference to the British National Formulary (BNF) and the British National Formulary for Children (BNFC). Aimed at UK NHS healthcare professionals involved with prescribing, monitoring, supplying and administering medicines; the app provides essential information on the selection of safe and effective medicines for individual patients.

Please read the app Terms and Conditions [http://www.bnf.org/products/bnfbnfcapp/bnf-bnf-app-terms-and-conditions/] carefully before using this mobile application. Downloading the app will indicate your acceptance. If you do not agree to these Terms and Conditions, you may not use the app.

Features include:
· Offline browsing and searching of content of the BNF and BNFC
· The ability to switch between adult and child content
· Autocomplete search with navigation panes for treatment summaries, drug monographs and medicinal products
· Powerful interactions checker
· Clinical content updated every month
· Update notifications when a new update is available
· Optimised for smart phones and tablets

BNF
Significant Changes:   

• Benralizumab for treating severe eosinophilic asthma [NICE guidance].
• Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib [NICE guidance].
• Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes [NICE guidance].
• Fluoroquinolone antibiotics (ciprofloxacin): new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects [MHRA/CHM advice].
• Fluoroquinolone antibiotics (levofloxacin, moxifloxacin, ofloxacin): new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects [MHRA/CHM advice].
• Irinotecan hydrochloride, liposomal formulations (Onivyde®): reports of serious and fatal thromboembolic events [MHRA/CHM advice].
• Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer [NICE guidance].
• Pneumococcal vaccine: updated guidance in-line with Public Health England recommendations.
• Prescribing in pregnancy: medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed? [MHRA/CHM advice].
• Respiratory system infections, antibacterial therapy: new guidance for acute exacerbations of Bronchiectasis (non-cystic fibrosis
• Respiratory system infections, antibacterial therapy: updated guidance for acute exacerbations of Chronic obstructive pulmonary disease.

Dose Changes:

• Alirocumab [Dosing options for Primary hypercholesterolaemia or mixed dyslipidaemia].

New Preparations: Buvidal® [buprenorphine], Erleada® [apalutamide], Fortacin® [lidocaine with prilocaine], Symkevi® [tezacaftor with ivacaftor], Tegsedi® [inotersen].

For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm

BNFC

Significant Changes: 

• Fluoroquinolone antibiotics (ciprofloxacin): new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects [MHRA/CHM advice].
• Pneumococcal vaccine: updated guidance in-line with Public Health England recommendations.
• Prescribing in pregnancy: medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed? [MHRA/CHM advice].
• Respiratory system infections, antibacterial therapy: new guidance for acute exacerbations of Bronchiectasis (non-cystic fibrosis)
  Dose Changes:
• Glycerol phenylbutyrate [Dose rounding recommendation for children under 2 years].

New Preparations: Maviret® [glecaprevir with pibrentasvir], Symkevi® [tezacaftor with ivacaftor].

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

Download link:

Mediafire